The Gammaplex Copay Program

The Gammaplex Copay Program is designed for patients who are having difficulty paying their out-of-pocket costs for their IVIG prescription.

**Patient eligibility:**
- Patients must express a need for financial assistance or difficulty paying copay.
- Patients must have coverage under a private US insurance plan.
- Patients whose insurance policy prohibits copay assistance are not eligible. Prior to enrolling, participants are responsible for checking with their insurance carrier to confirm that their participation is not inconsistent with their plan’s requirements.

**Benefit:**
- Patients can receive up to $2000 in assistance per calendar year.
- Up to $1000 is available at first fill and $250 for subsequent fills up to annual maximum.

For more information and complete program rules please visit gammaplex.medmonk.com or call 1-866-234-3732

Please see Important Safety Information on back and full prescribing information in pocket.
Patient eligibility:

- out-of-pocket costs for their IVIG prescription.

The Gammaplex Copay Program is designed for patients who are having difficulty paying their IVIG prescription. Patients can receive up to $2000 in assistance per calendar year or call 1-866-234-3732. For more information and complete program rules please visit gammaplex.medmonk.com. The Gammaplex Copay Program administered by the [MedMonk Program Management Company].

Important Safety Information

Gammaplex® (immune globulin intravenous [human], 5% liquid) is indicated for replacement therapy in primary humoral immunodeficiency (PI) in adults and pediatric patients two years of age and older. This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Gammaplex is also indicated for the treatment of chronic immune thrombocytopenic purpura (ITP).

Thrombosis may occur with immune globulin products, including Gammaplex. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hypersensitivity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.

Renal dysfunction, acute renal failure, somnolence and death may occur in predisposed patients who receive immune globulin intravenous (IGIV) products, including Gammaplex.

Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Gammaplex does not contain sucrose.

For patients at risk of thrombosis, renal dysfunction or acute renal failure, administer Gammaplex at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Gammaplex is contraindicated in patients who have had a history of anaphylactic or severe systemic reactions to human immune globulin; a hereditary intolerance to fructose and in infants and neonates for whom sucrose or fructose tolerance has not been established; and/or, deficient patients with antibodies to IgA and a history of hypogammaglobulinemia.

In patients at risk of developing acute renal failure, monitor renal function, including blood urea nitrogen (BUN), serum creatinine and urine output. Hyperviscosity, increased serum viscosity, and hyperviscosity may occur in patients receiving IGIV therapy.

Aseptic meningitis syndrome (AMS) may occur infrequently with IGIV treatment. AMS usually begins within several hours to 2 days following IGIV treatment. Decongestion of IGIV treatment has resulted in remission of AMS within several days without sequelae. AMS may occur more frequently in association with high doses (>2 g/kg) and/or rapid infusion of IGIV.

Hemolysis and hemolytic anemia can develop subsequent to IGIV treatment. Patient risk factors that may be associated with development of hemolysis include high dose (>2 g/kg), non-O blood group, and underlying inflammatory state. Nephrotoxic cardiopulmonary edema can occur in patients following IGIV treatment (i.e., transudative acute lung injury [TRALI]). Monitor patients for pulmonary adverse reactions. If TRALI is suspected, test product and patients serum for anti-neutrophil antibodies.

Gammaplex is manufactured by Bio Products Laboratory Limited, Hertfordshire, WD6 3BX, United Kingdom.